Ocugen, Inc. (NASDAQ:OCGN - Get Free Report) was the target of some unusual options trading activity on Monday. Stock investors acquired 4,596 call options on the stock. This is an increase of approximately 93% compared to the average volume of 2,382 call options.
Analyst Ratings Changes
Separately, HC Wainwright reaffirmed a "buy" rating and set a $7.00 price target on shares of Ocugen in a report on Wednesday, April 3rd.
Check Out Our Latest Analysis on Ocugen
Institutional Investors Weigh In On Ocugen
Several institutional investors and hedge funds have recently modified their holdings of OCGN. WINTON GROUP Ltd bought a new stake in shares of Ocugen during the first quarter valued at approximately $25,000. Belpointe Asset Management LLC increased its position in Ocugen by 11,550.5% in the first quarter. Belpointe Asset Management LLC now owns 34,835 shares of the company's stock worth $30,000 after purchasing an additional 34,536 shares during the last quarter. Two Sigma Securities LLC bought a new stake in Ocugen in the second quarter worth $32,000. Schonfeld Strategic Advisors LLC bought a new stake in Ocugen in the second quarter worth $32,000. Finally, Lazard Asset Management LLC increased its position in Ocugen by 123.9% in the second quarter. Lazard Asset Management LLC now owns 61,432 shares of the company's stock worth $32,000 after purchasing an additional 33,991 shares during the last quarter. Institutional investors own 10.27% of the company's stock.
Ocugen Price Performance
NASDAQ:OCGN traded up $0.05 during trading hours on Monday, hitting $1.88. 19,511,787 shares of the stock traded hands, compared to its average volume of 8,283,970. The company has a market cap of $482.22 million, a price-to-earnings ratio of -5.97 and a beta of 3.51. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.03. Ocugen has a 1 year low of $0.35 and a 1 year high of $2.11. The stock has a 50 day moving average price of $1.02 and a 200 day moving average price of $0.64.
Ocugen Company Profile
(
Get Free Report)
Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD.
Read More
Before you consider Ocugen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ocugen wasn't on the list.
While Ocugen currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
